User login
Key clinical point: Fecal and intestinal mucosal microbiota are distinctly different in patients with constipation-predominant or diarrhea-predominant irritable bowel syndrome (IBS-C or IBS-D), with microbiota changes being correlated with clinical manifestations of IBS.
Major finding: Community richness and diversity of the fecal microbiota were significantly lower in patients with IBS-C or IBS-D vs healthy controls (HC; P < .05). The fecal microbiota showed a shift in the abundance of Bacteroides caccae and Roseburia (both P < .05) in patients with IBS vs HC, with both correlating with abdominal pain and distension (P < .05). In terminal ileum, Bifidobacterium and Eubacterium correlated with abdominal pain (P < .05).
Study details: This study evaluated fecal and intestinal mucosal samples from 14 patients with IBS-C, 20 patients with IBS-D, and 20 HC.
Disclosures: This study was funded by the Projects of Science and Technology for Social Development and the Innovation Engineering Project of Science and Technology in Shaanxi Province, China. The authors declared no conflicts of interest.
Source: Hou Y et al. Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome. Dig Dis Sci. 2022 (Jul 25). Doi: 10.1007/s10620-022-07588-4
Key clinical point: Fecal and intestinal mucosal microbiota are distinctly different in patients with constipation-predominant or diarrhea-predominant irritable bowel syndrome (IBS-C or IBS-D), with microbiota changes being correlated with clinical manifestations of IBS.
Major finding: Community richness and diversity of the fecal microbiota were significantly lower in patients with IBS-C or IBS-D vs healthy controls (HC; P < .05). The fecal microbiota showed a shift in the abundance of Bacteroides caccae and Roseburia (both P < .05) in patients with IBS vs HC, with both correlating with abdominal pain and distension (P < .05). In terminal ileum, Bifidobacterium and Eubacterium correlated with abdominal pain (P < .05).
Study details: This study evaluated fecal and intestinal mucosal samples from 14 patients with IBS-C, 20 patients with IBS-D, and 20 HC.
Disclosures: This study was funded by the Projects of Science and Technology for Social Development and the Innovation Engineering Project of Science and Technology in Shaanxi Province, China. The authors declared no conflicts of interest.
Source: Hou Y et al. Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome. Dig Dis Sci. 2022 (Jul 25). Doi: 10.1007/s10620-022-07588-4
Key clinical point: Fecal and intestinal mucosal microbiota are distinctly different in patients with constipation-predominant or diarrhea-predominant irritable bowel syndrome (IBS-C or IBS-D), with microbiota changes being correlated with clinical manifestations of IBS.
Major finding: Community richness and diversity of the fecal microbiota were significantly lower in patients with IBS-C or IBS-D vs healthy controls (HC; P < .05). The fecal microbiota showed a shift in the abundance of Bacteroides caccae and Roseburia (both P < .05) in patients with IBS vs HC, with both correlating with abdominal pain and distension (P < .05). In terminal ileum, Bifidobacterium and Eubacterium correlated with abdominal pain (P < .05).
Study details: This study evaluated fecal and intestinal mucosal samples from 14 patients with IBS-C, 20 patients with IBS-D, and 20 HC.
Disclosures: This study was funded by the Projects of Science and Technology for Social Development and the Innovation Engineering Project of Science and Technology in Shaanxi Province, China. The authors declared no conflicts of interest.
Source: Hou Y et al. Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome. Dig Dis Sci. 2022 (Jul 25). Doi: 10.1007/s10620-022-07588-4